Oramed Pharmaceuticals
ORMP
28 hedge funds and large institutions have $8.45M invested in Oramed Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
331% more capital invested
Capital invested by funds: $1.96M → $8.45M (+$6.49M)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
33% more funds holding
Funds holding: 21 → 28 (+7)
8.2% more ownership
Funds ownership: 1.83% → 10.03% (+8.2%)
0% more call options, than puts
Call options by funds: $4K | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.16M |
| 2 |
AC
Armistice Capital
New York
|
+$3.24M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$93.5K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$87.8K |
| 5 |
Squarepoint
New York
|
+$75.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$63.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$25.8K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$5.19K |
| 4 |
LC
Landaas & Company
Milwaukee,
Wisconsin
|
-$2K |
| 5 |
Morgan Stanley
New York
|
-$26 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LTFS
26
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
27
Simplex Trading
Chicago,
Illinois
| $2K | +$2.84K | +547 | New |
|
|
SPIA
28
Steward Partners Investment Advisory
New York
| $1K | – | – | – |
|
|
LC
29
Landaas & Company
Milwaukee,
Wisconsin
| – | -$2K | -230 | Closed |
|
ORMP Hedge Fund Activity: Q3 2018 in Review
28 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2018, worth a combined $8.45M — up 331% from $1.96M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ORMP positions and 1 closed out — a net gain of 7 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $4.16M. The largest seller was Renaissance Technologies, cutting an estimated $63.6K.
- 28 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2018, up from 21 in Q2 2018.
- Funds reported $8.45M of Oramed Pharmaceuticals stock for Q3 2018, up 331% quarter-over-quarter.
- 8 funds opened new Oramed Pharmaceuticals positions in Q3 2018 and 1 closed out, a net change of +7 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2018 was Sabby Management, an estimated $4.16M added.
- The largest Oramed Pharmaceuticals seller in Q3 2018 was Renaissance Technologies, an estimated $63.6K sold.
Based on aggregated 13F filings for Q3 2018.